Press conference moderator William G. Woods, MD, Pediatric Hematology/Oncology Director and the Daniel P. Amos Children’s Chair, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, called the phase III FRALLE trial “an important confirmatory step regarding the front-line treatment of childhood ALL using the most modern day therapy.”
“Reducing anthracycline exposure will not impede outcomes. We know that anthracyclines are still needed in smaller doses, but the hope is that someday we will be able to eliminate them by substitution of other drugs, especially novel drugs that may not be invented yet,” Dr. Woods said. ■
Disclosure: Dr. Woods reported no potential conflicts of interest.
Omitting daunorubicin from induction therapy for children with standard-risk acute B-cell lymphoblastic leukemia (ALL) does not compromise survival and at the same time reduces the risk of associated toxicities, including myelosuppression and cardiac damage, according to results of the large phase...